Alzamend Neuro Q1 FY27 net loss narrows 12% to $3.03 million - ALZN News | RalliesAlzamend Neuro Q1 FY27 net loss narrows 12% to $3.03 million
A
ALZN• Q1 FY27 results
- Alzamend Neuro posted a net loss of $3.03 million, widening 12% from a year earlier.
- Operating loss widened to $3.03 million as total operating expenses rose 12% to $3.03 million.
- Research and development spending fell 38% to $1.09 million, driven by lower clinical trial fees.
- General and administrative costs more than doubled to $1.94 million on higher professional fees, including legal costs tied to the Biorasi lawsuit.
- Cash totaled $7.6 million; it raised $7.4 million from Series D Preferred Stock, adding $669,000 from its at-the-market offering.
•
